Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.36 |
| ▸ | GCGR | P47871 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | FRK | P42685 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717762 | 0.93 | ABCB1 (0.68) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL6625154 | 0.90 | ABCB1 (0.69) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL13679647 | 0.88 | ABCB1 (0.53) | ABCB1NOX1MAPTMEN1KMT2A | |
| SCHEMBL13679656 | 0.84 | ABCB1 (0.70) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL3828912 | 0.84 | ABCB1 (0.69) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL13679689 | 0.82 | ABCB1 (0.73) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL6621640 | 0.81 | ABCB1 (0.57) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL3826448 | 0.81 | ABCB1 (1.00) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL719051 | 0.81 | ABCB1 (0.74) | ABCB1NOX1PTPN1ALOX5MAPT | |
| SCHEMBL719050 | 0.81 | ABCB1 (1.00) | ABCB1NOX1PTPN1ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | claimed |
| EP-0999835-B1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | TAIJI BIOMEDICAL INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1221847-B1 | METHODS OF ENHANCING CHEMOTHERAPY | TAIJI BIOMEDICAL INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | ABCB1 21/4885NOX1 3939/4885PTPN1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.